Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are tied to a reduction in alcohol intake, according to a research ...

Liraglutide and semaglutide reduce alcohol intake, cutting it by nearly two-thirds within four months of treatment.

You may have heard of "Ozempic face" and "Ozempic butt." Well, now there's "Ozempic mouth" and "Ozempic feet" to describe ...

GLP-1 receptor agonists are reshaping obesity care. OHE highlights access challenges, prescribing policy, and how patient and ...

News Evidence That GLP-1 Drugs Achieve Weight Loss Primarily by Reducing Fat Mass More Than Muscle. Diabetes and obesity have become pressing health issues worldwide. Glucagon-lik ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can lead to significant weight loss and improve blood sugar control in adults with severe mental illness, as well as having positive effects on ...

First-generation GLP-1 weight-loss drugs can help reduce the risk of obesity-related cancers, new research shows. Liraglutide ...

Children who are living with severe obesity are more likely to experience a clinically relevant change in BMI when GLP-1 agonist drugs form part of their treatment, new research being presented at ...

Landmark research suggests the appetite-suppressing jabs which mimic a hormone that makes us feel full also significantly cut ...

GLP-1 RAs are associated with a significant decrease in apnea-hypopnea index among patients with moderate to severe OSA and without diabetes.